Breaking News
Rapport Therapeutics Inc (RAPP) Reports a Wider Loss for Q4 2025
Rapport Therapeutics Inc (RAPP) posted a Q4 2025 gaap loss of $0.72 per share, wider than the -$0.67 expected loss (6.8% wider). The clinical-stage biophar...